论文部分内容阅读
目的比较CHOP-14与CHOP-21方案治疗弥漫性大B细胞淋巴瘤的疗效及不良反应。方法48例初治弥漫性大B细胞淋巴瘤随机分为治疗组和对照组,每组24例,治疗组采用CHOP-14方案治疗,在化疗第5天开始给予G-CSF支持治疗,预防白细胞下降。对照组采用常规CHOP-21方案治疗。CHOP方案:CTX750mg/m2,第1天;ADM50mg/m2,第1天;VCR1.4mg/m2,第1天;PDN100mg,第1～5天。结果治疗组有效率为97.05%,对照组有效率为79.41%(P<0.05)。两组患者的不良反应发生情况差异无统计学意义(P>0.05)。结论CHOP-14方案治疗弥漫性大B细胞淋巴瘤是一种安全、有效的治疗方案。
Objective To compare the efficacy and adverse reactions of CHOP-14 and CHOP-21 regimen in the treatment of diffuse large B cell lymphoma. Methods 48 cases of newly diagnosed diffuse large B-cell lymphoma were randomly divided into treatment group and control group, 24 cases in each group. The treatment group was treated with CHOP-14 regimen. G-CSF supportive treatment was started on the 5th day of chemotherapy to prevent leucocyte decline. Control group using conventional CHOP-21 regimen. CHOP regimen: CTX 750 mg / m 2 on day 1 ADM 50 mg / m 2 on day 1 VCR 1.4 mg / m 2 on day 1 PDN 100 mg on day 1 to 5. Results The effective rate was 97.05% in the treatment group and 79.41% in the control group (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion CHOP-14 regimen is a safe and effective treatment for diffuse large B-cell lymphoma.